1. This does not cost the company $13 million dollars. It cost the company $1,771.00 plus some legal fees.
2. Unless the stock is above $21.85 when these are exercised, they won't be exercised.
3. Hopefully the majority of these are to incentivize new employess for joining company or to reward and encourage employees to stay with the company.
4. Yes, if exercised they are dilutive. But they also could add $13 million dollars to cash position someday.
All that said, I agree CG personally gets way to many options for his performance.
There were past indications that the PMO+ drugs were contracted out. As I recall there may have been a PR stating an issue at a subcontractor with the PMO+ at one time or possibly it was in a transcript.
I agree with you also. The bothersome thing is another trial should have been planned and started to increase the population once it was clear the drug worked. And that was almost 2 years ago!
I agree with you! It is why I made a graphic showing the slip and posted it. Maybe I should have played nice and also mailed it to Sarepta. The repeated revising and slipping schedules is getting very tiring. I am sure many of these things are beyond Sarepta's control, but still some delays are pure decisions.
ROFLMAO -- There are many more folks at Sarepta than Garabedian! Jayant Aphale sounds like he has the general experience to lead up the manufacturing.
I agree with you they need alignment with the FDA, but even a listing on clinicaltrials gov would give a slight smoke signal of progress and many companies list and then tweak. What concerns me, is it seems there is a never ending pattern of slipping.
Hopefully the BOD gave Chris the signal that he has to stop slippage.
The EU 4053 trial also has slipped from the schedule, though the slippage appears to be only a few months over a couple years.
Looking at the difference between the July/August presentationa and the September presentation, it is alarming that it appears the start of the open label ambulant trial has been slipping about at a month per month rate.
See the PDF I posted at IV!
Why isn't there at least 1 trial listed at clinicaltrials? There really should be at least two! The Eteplirsen in ambulant boys and the EU's 4053 open label study! Originally they were supposed to be dosing now.
Terrifying number of events Sarepta has to finish in the last 3.5 months of the year!
we only have a very good idea Sarepta's ebola treatment safe in humans at higher doses, based on the combo ebola trial & marburg similiarity plus the primate studies. Hard to imagine there is not a dose response curve until some saturation point is reached. The half life of the drug will remain unchanged with the dose, BUT if you double the dose, at 1 half life, you will still have twice as much drug in the patients system. obviously there are limits to where you can go in increasing dose till you lose effectiveness in increased amounts or ... Recall Iversen who did initial ebola work was at Nebraska before AVII
The issue with your faulty thinking (?) is that you assume dystrophin level alone would be adequate alone to predict performance and performance measurement.
I suspect you realize it is not dystrophin level alone, but also muscle mass. Percentage of muscle versus fiber. and a host of other variables. I suspect the FDA understands this also. But you live in this world where you take pleasure in trying to mislead others.
One theory is this outbreak is in an area where ebola outbreaks are not so normal. It is possible the areas where outbreaks are more common, that the population has built up a certain amount of antibodies. Possibly this is from eating improperly prepared bush meat or mild cases passed around.
Viral transmission is a role of the dice.
Ebola can be present in sperm up to 60 days after a male has been "cured"!
One question that I have not heard the answer to is are there carriers who are not symptomatic?
If a couple of people escape from Africa and contaminate a couple of jumbo jets full of people, this could turn in to a worldwide nightmare.
Just imagine even 50 contaminated people arriving in London. How many will be on flights to the US, Hong Kong, Tokyo, Western Europe before it is recognized they have the disease.
Look at the spread of HIV and imagine, if this gets loose in a promiscuous group.
Twitter is not ablaze with this. One MD who was previously bullish is now spouting this, without giving any reason. A DMD trial update is promised next week. I suspect we will hear good things about the confimratory trial start. Maybe not great things though.
Most likely scenario is approval in 2015.
quite possibly the real emergency in the world is people like you, who are really unable to think in a rational manner. And as for ebola, bringing victims to the US should terrify you! The people responsible didn't no they had vails of the smallpox virus they failed to destroy for years. And you expect us to trust their experts?
makes sense, but one thing if I recall correctly is the primate testing used very large amount(?) of ebola to infect the primate. Therefore, I would think if they identified people by blood testing for ebola rather than waiting for symptoms, they might have reasonable candidates for proving the drug works.
The incubation period, that is, the time interval from infection with the virus to onset of symptoms, is 2 to 21 days.
And this POTUS has proceeded to do all kinds of things he couldn't do. And many of his predecessors did also.
If it's to happen, it will be because the government wants it done and the goverment will pick up the expense.
Again you remind me of a guy I fired years ago, because he couldn't find his way around obstacles.
I sure am not betting on ebola helping Sarepta, but it would be smart, if the goverment used this as a chance to prove whether their investment made sense and if this does turn into an intercontinental issue....
mauouo, if you look at the half life or Eteplirsen, it is obvious that anything resulting in Eteplirsen being in the blood stream for a higher percentage of time is likely to improve the time to increase dystrophin. It follows this would improve the 6 MWT. This might be a pump or a dosing frequency greater than once a week. Now once a bouy has increased dystrophin at some level, this probably doesn't make sense. But for that period between 12 and 24 or maybe greater weeks, the higher percentage of time the dells are exposed to the morpholino, probably the greater increase in dystrophin. And yes this will translate most likely into improved 6MWT results.
There is certainly exciting stuff going on behind the scenes. Just search the patent applications. Now if they only get DMD across hte finish line!
RP tossed mud left and right. If you read my replies to him, you will find I caught him in a number of lies.
He makes the assumption a truncated gene will not work because of some BS he spouts about evolutionary biology. We know for a fact the dystrophin gene in boys with Becker's works and that it is truncated from the normal dystrophin gene. We know that the exon skipping works in the mouse model, works in the dog model, and there are strong indications it works in human model based on the 6 MWT results.
It is hard to beleive Mendell, Muntoni, and others would be willing to risk their reputation by mistating information about dystrophin, both have had this information published in peer reviewed articles.
The Claims area of the patent to a large extent are all all that matter. The part that matters about the rest of it is 1) convincing that the invention is not prior art. 2) Enabling the invention. The mention of Sarepta's drugs were in these latter sections rather than the claims, so I give them little credence. This isn't the first device oriented patent where Cook has mentioned these. Some of these things are largely copied from patent to patent. No reason to reinvent the world in this area of the patent.
Unless Cook comes back to Sarepta for an antisense compound, I see no impact. The claims of the patent are all directed to the mechanical construction of the catheter. Besides Resten-NG and Resten-MP there are a number of compunds which there may be reason to have local delivery with such a device including FDA approved drugs: rapamycin, paclitaxel.
Possibly a more interesting patent 8,785,410 Iversen , et al. July 22, 2014 Antisense composition and method for treating muscle atrophy
makes a lot of sense. reimbursement and a possible drisapersen approval or the twon unnowns once Eteplirsen approved. Insurance may push cheapest drug